EA007565B1 - Применение конъюгатов желчной кислоты или соли желчной кислоты с жирными кислотами для лечения жировой инфильтрации печени - Google Patents

Применение конъюгатов желчной кислоты или соли желчной кислоты с жирными кислотами для лечения жировой инфильтрации печени Download PDF

Info

Publication number
EA007565B1
EA007565B1 EA200301017A EA200301017A EA007565B1 EA 007565 B1 EA007565 B1 EA 007565B1 EA 200301017 A EA200301017 A EA 200301017A EA 200301017 A EA200301017 A EA 200301017A EA 007565 B1 EA007565 B1 EA 007565B1
Authority
EA
Eurasian Patent Office
Prior art keywords
acid
fatty
bile
liver
bond
Prior art date
Application number
EA200301017A
Other languages
English (en)
Russian (ru)
Other versions
EA200301017A1 (ru
Inventor
Тувиа Гилат
Original Assignee
Галмед Интернэшнл Лимитид
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Галмед Интернэшнл Лимитид filed Critical Галмед Интернэшнл Лимитид
Publication of EA200301017A1 publication Critical patent/EA200301017A1/ru
Publication of EA007565B1 publication Critical patent/EA007565B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Botany (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
EA200301017A 2001-04-17 2002-04-15 Применение конъюгатов желчной кислоты или соли желчной кислоты с жирными кислотами для лечения жировой инфильтрации печени EA007565B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL142650A IL142650A (en) 1998-04-08 2001-04-17 Use of bile acid conjugates or bile salts and fatty acids or fatty acids in the preparation of pharmaceuticals for lowering cholesterol, for the treatment of fatty liver and for the treatment of hyperglycemia and diabetes
PCT/IL2002/000303 WO2002083147A1 (en) 2001-04-17 2002-04-15 Use of bile acid or bile salt fatty acid conjugates

Publications (2)

Publication Number Publication Date
EA200301017A1 EA200301017A1 (ru) 2005-04-28
EA007565B1 true EA007565B1 (ru) 2006-12-29

Family

ID=11075322

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200301017A EA007565B1 (ru) 2001-04-17 2002-04-15 Применение конъюгатов желчной кислоты или соли желчной кислоты с жирными кислотами для лечения жировой инфильтрации печени

Country Status (24)

Country Link
US (2) US7501403B2 (enExample)
EP (2) EP1379254B1 (enExample)
JP (1) JP4324706B2 (enExample)
KR (1) KR100883080B1 (enExample)
CN (1) CN1259918C (enExample)
AT (2) ATE432705T1 (enExample)
AU (2) AU2002307771B2 (enExample)
BR (1) BR0208924A (enExample)
CA (2) CA2444266C (enExample)
CY (1) CY1106853T1 (enExample)
CZ (2) CZ309042B6 (enExample)
DE (2) DE60232559D1 (enExample)
DK (2) DK1379254T3 (enExample)
EA (1) EA007565B1 (enExample)
ES (2) ES2289137T3 (enExample)
HU (1) HU230548B1 (enExample)
IL (1) IL142650A (enExample)
MX (1) MXPA03009553A (enExample)
NO (2) NO333910B1 (enExample)
NZ (1) NZ528868A (enExample)
PL (2) PL211438B1 (enExample)
PT (2) PT1379254E (enExample)
UA (1) UA78699C2 (enExample)
WO (1) WO2002083147A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL142650A (en) 1998-04-08 2007-06-03 Galmed Int Ltd Use of bile acid conjugates or bile salts and fatty acids or fatty acids in the preparation of pharmaceuticals for lowering cholesterol, for the treatment of fatty liver and for the treatment of hyperglycemia and diabetes
US8975246B2 (en) 2001-04-17 2015-03-10 Galmed Research And Development Ltd. Bile acid or bile salt fatty acid conjugates
PT2182954T (pt) * 2007-07-25 2019-02-06 Univ Graz Medizinische Utilização de ácidos nor-biliares no tratamento de arteriosclerose
US9314444B2 (en) 2009-01-12 2016-04-19 Biokier, Inc. Composition and method for treatment of NASH
KR20170138573A (ko) 2009-01-12 2017-12-15 바이오키어 인코포레이티드 당뇨병 치료 조성물 및 치료방법
US9006288B2 (en) 2009-01-12 2015-04-14 Biokier, Inc. Composition and method for treatment of diabetes
EP2391370B1 (en) 2009-02-02 2015-06-03 Galmed Research and Development Ltd. Methods and compositions for treating alzheimer's disease
US20120202890A1 (en) 2011-02-08 2012-08-09 Nian Wu Polymer-carbohydrate-lipid conjugates
AU2013256362A1 (en) * 2012-05-01 2014-11-13 Catabasis Pharmaceuticals, Inc. Fatty acid conjugates of statin and FXR agonists: compositions and methods of use
CN103571617A (zh) * 2012-07-26 2014-02-12 丰益(上海)生物技术研发中心有限公司 改进的动物油脂加工工艺
ES2701077T3 (es) 2012-11-29 2019-02-20 St Pharm Co Ltd Conjugado de oligómero de ácido biliar para un nuevo transporte vesicular y uso del mismo
IL227890A0 (en) * 2013-08-08 2014-01-30 Galderm Therapeutics Ltd Antiaging compounds containing bile acid and fatty acid conjugates
US11571431B2 (en) 2013-12-04 2023-02-07 Galmed Research And Development Ltd Aramchol salts
ES2732845T3 (es) * 2013-12-04 2019-11-26 Galmed Res & Development Ltd Sales de Aramchol
CN106413719A (zh) * 2014-06-01 2017-02-15 盖尔梅德研究与发展有限公司 用于治疗脂肪营养不良的脂肪酸胆汁酸缀合物
US10849911B2 (en) 2015-06-10 2020-12-01 Galmed Research And Development Ltd. Low dose compositions of Aramachol salts
IL243707A0 (en) 2016-01-20 2016-05-01 Galmed Res And Dev Ltd Treatment to regulate the microbiota in the intestine
US11197870B2 (en) 2016-11-10 2021-12-14 Galmed Research And Development Ltd Treatment for hepatic fibrosis
CN116687850A (zh) 2022-02-24 2023-09-05 甘莱制药有限公司 包含环状膦酸酯化合物的药物组合物及其制备方法与用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3856953A (en) * 1973-05-15 1974-12-24 Intellectual Property Dev Corp Method of treating fatty liver
WO1999052932A1 (en) * 1998-04-08 1999-10-21 Galmed International Ltd. Fatty acid derivatives of bile acids and bile acid derivatives

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3859437A (en) * 1972-06-02 1975-01-07 Intellectual Property Dev Corp Reducing cholesterol levels
IT1167479B (it) * 1981-07-24 1987-05-13 Carlo Scolastico Derivati dell'acido chenodesossicolico
IT1167478B (it) * 1981-07-24 1987-05-13 Carlo Scolastico Derivati dell'acido ursodesossicolico
JPS6164701A (ja) * 1984-09-06 1986-04-03 Meito Sangyo Kk カチオン化デキストラン誘導体とポリウロン酸の高分子電解質錯体及びその利用
DE3930696A1 (de) * 1989-09-14 1991-03-28 Hoechst Ag Gallensaeurederivate, verfahren zu ihrer herstellung, verwendung als arzneimittel
US5278320A (en) * 1992-09-11 1994-01-11 Merck & Co., Inc. Cholesterol lowering compounds produced by directed biosynthesis
DE4432708A1 (de) * 1994-09-14 1996-03-21 Hoechst Ag Modifizierte Gallensäuren, Verfahren zu ihrer Herstellung und ihre Verwendung
US6576660B1 (en) * 1997-10-31 2003-06-10 Arch Development Corporation Methods and compositions for regulation of 5-α-reductase activity
US20030153541A1 (en) * 1997-10-31 2003-08-14 Robert Dudley Novel anticholesterol compositions and method for using same
IL142650A (en) 1998-04-08 2007-06-03 Galmed Int Ltd Use of bile acid conjugates or bile salts and fatty acids or fatty acids in the preparation of pharmaceuticals for lowering cholesterol, for the treatment of fatty liver and for the treatment of hyperglycemia and diabetes
US6620821B2 (en) * 2000-06-15 2003-09-16 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
JP2006306800A (ja) * 2005-04-28 2006-11-09 Kirin Brewery Co Ltd ファルネソイドｘ受容体活性化剤

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3856953A (en) * 1973-05-15 1974-12-24 Intellectual Property Dev Corp Method of treating fatty liver
WO1999052932A1 (en) * 1998-04-08 1999-10-21 Galmed International Ltd. Fatty acid derivatives of bile acids and bile acid derivatives

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GILAT, T. ET AL.: "Arachidyl amido cholanoic acid (Aramchol) is a cholesterol solubilizer and prevents the formation of cholesterol gallstones in inbred mice." LIPIDS. UNITED STATES OCT. 2001, vol. 36, no. 10, October 2001 (2001-10), pages 1135-1140, XP001084450, ISSN: 0024-4201, page 1139, column 2, line 22 - line 24, abstract *
GILAT, T. ET AL.: "Fatty acid bile acid conjugates (FABACs) - New molecules for the prevention of cholesterol crystallisation in bile". GUT, vol. 48, no. 1, January 2001 (2001-01), pages 75-79, XP001084451, ISSN: 0017-5749, abstract, page 78, column 2, line 40 -page 79, column 1, line 3, page 75, column 2, line 48 -page 76, column 1, line 12; figure 1 *

Also Published As

Publication number Publication date
CA2703688C (en) 2012-07-31
EP1379254B1 (en) 2007-06-20
ES2328966T3 (es) 2009-11-19
KR100883080B1 (ko) 2009-02-10
HU230548B1 (hu) 2016-11-28
AU2007200191B2 (en) 2008-09-04
PT1379254E (pt) 2007-07-10
CA2444266A1 (en) 2002-10-24
US7501403B2 (en) 2009-03-10
HUP0400801A2 (hu) 2004-08-30
DK1379254T3 (da) 2007-10-15
US20090149537A1 (en) 2009-06-11
HUP0400801A3 (en) 2012-09-28
MXPA03009553A (es) 2004-05-24
US8110564B2 (en) 2012-02-07
DK1790346T3 (da) 2009-10-12
DE60220775T2 (de) 2008-03-06
PL211438B1 (pl) 2012-05-31
EP1790346A3 (en) 2007-08-22
CA2444266C (en) 2010-07-27
CY1106853T1 (el) 2012-05-23
CN1529603A (zh) 2004-09-15
NO20131219L (no) 2003-11-28
DE60220775D1 (de) 2007-08-02
IL142650A (en) 2007-06-03
US20040121993A1 (en) 2004-06-24
PL205057B1 (pl) 2010-03-31
CA2703688A1 (en) 2002-10-24
UA78699C2 (en) 2007-04-25
ES2289137T3 (es) 2008-02-01
WO2002083147A1 (en) 2002-10-24
PT1790346E (pt) 2009-09-04
NO20034609D0 (no) 2003-10-15
BR0208924A (pt) 2004-04-20
EA200301017A1 (ru) 2005-04-28
CZ20032710A3 (cs) 2004-04-14
AU2002307771B2 (en) 2006-10-19
NO333910B1 (no) 2013-10-14
IL142650A0 (en) 2002-03-10
NZ528868A (en) 2005-09-30
CZ309042B6 (cs) 2021-12-22
EP1790346A2 (en) 2007-05-30
CZ2008296A3 (enExample) 2004-04-14
JP4324706B2 (ja) 2009-09-02
DE60232559D1 (de) 2009-07-16
NO20034609L (no) 2003-11-28
CN1259918C (zh) 2006-06-21
CZ300489B6 (cs) 2009-06-03
KR20030092063A (ko) 2003-12-03
AU2007200191A1 (en) 2007-02-08
EP1790346B1 (en) 2009-06-03
JP2004525962A (ja) 2004-08-26
NO335087B1 (no) 2014-09-08
PL366585A1 (en) 2005-02-07
EP1379254A1 (en) 2004-01-14
ATE432705T1 (de) 2009-06-15
ATE365044T1 (de) 2007-07-15

Similar Documents

Publication Publication Date Title
EA007565B1 (ru) Применение конъюгатов желчной кислоты или соли желчной кислоты с жирными кислотами для лечения жировой инфильтрации печени
US11185591B2 (en) Methods of making and using polyphenols complexed with a protein, peptide, amino acid, polysaccaride, disaccharide, or monosaccharide
US8975246B2 (en) Bile acid or bile salt fatty acid conjugates
AU2002307771A1 (en) Use of bile acid or bile salt fatty acid conjugates
JP2009523435A (ja) 診断方法及び治療方法
CN103002736B (zh) 治疗葡萄糖代谢紊乱的方法
Nishigori et al. Analysis of glucose levels during glucocorticoid-induced cataract formation in chick embryos.
Cohen et al. Aspirin does not inhibit cholesterol cholelithiasis in two established animal models
Klimis-Tavantzis et al. The effect of dietary manganese deficiency on cholesterol and lipid metabolism in the estrogen-treated chicken and the laying hen
RU2762221C1 (ru) Препарат комплексный с гепатопротекторной активностью для овец
Hedemann et al. Distinct difference in absorption pattern in pigs of betaine provided as a supplement or present naturally in cereal dietary fiber
JP3029902B2 (ja) 血清脂質増加剤
JP2012518641A (ja) 脂肪腫および脂肪肉腫を治療する方法
Leveille et al. Effect of dietary lithocholic acid on liver size of the chick
JP2531273B2 (ja) カルシウム吸収促進組成物
AU2008249537A1 (en) Use of bile acid or bile salt fatty acid conjugates
MINAMINO et al. Undernutrition due to a low-protein diet affects iron, zinc, and copper metabolism
JP2017533176A (ja) ジヒドロコレステロールの使用

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM MD TJ TM

PC4A Registration of transfer of a eurasian patent by assignment